NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

Munechika Enjoji, Kazuyuki MacHida, Motoyuki Kohjima, Masaki Kato, Kazuhiro Kotoh, Kazuhisa Matsunaga, Manabu Nakashima, Makoto Nakamuta

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. However, dietary cholesterol intake was superabundant in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Therefore, excess cholesterol intake appears to be one of the main factors associated with NAFLD development and liver injury. Methods. We reviewed a year of follow-up data of non-obese NAFLD patients treated with Niemann-Pick C1 like 1 inhibitor ezetimibe to evaluate its therapeutic effect on clinical parameters related to NAFLD. Without any dietary or exercise modification, 10 mg/day of ezetimibe was given to 8 patients. In 4 of 8 patients, ezetimibe was administered initially. In the remaining 4 patients, medication was switched from ursodeoxycholic acid to ezetimibe. Results: In each patient, body mass index was maintained under 25 kg/m2 during the observation period. Serum ALT levels significantly decreased within 6 months and in 4 patients levels reached the normal range (<30 U/L), which was accompanied with at least a 10% decrease in serum total cholesterol and LDL-cholesterol. However, ultrasonographic findings of fatty liver did not show obvious improvement for a year. Conclusion: We conclude that the cholesterol absorption inhibitor ezetimibe can suppress hepatic injury in non-obese patients with NAFLD and that ezetimibe may offer a novel treatment for NAFLD.

Original languageEnglish
Article number29
JournalLipids in Health and Disease
Volume9
DOIs
Publication statusPublished - Dec 1 2010

Fingerprint

Liver
Therapeutics
Anticholesteremic Agents
Dietary Cholesterol
Non-alcoholic Fatty Liver Disease
Ezetimibe
Ursodeoxycholic Acid
Cholesterol
Adipokines
Dietary Fats
Abdominal Fat
LDL Cholesterol
Wounds and Injuries
Therapeutic Uses
Fatty Liver
Energy Intake
Serum
Carbohydrates
Insulin Resistance
Insulin

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. / Enjoji, Munechika; MacHida, Kazuyuki; Kohjima, Motoyuki; Kato, Masaki; Kotoh, Kazuhiro; Matsunaga, Kazuhisa; Nakashima, Manabu; Nakamuta, Makoto.

In: Lipids in Health and Disease, Vol. 9, 29, 01.12.2010.

Research output: Contribution to journalArticle

Enjoji, Munechika ; MacHida, Kazuyuki ; Kohjima, Motoyuki ; Kato, Masaki ; Kotoh, Kazuhiro ; Matsunaga, Kazuhisa ; Nakashima, Manabu ; Nakamuta, Makoto. / NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. In: Lipids in Health and Disease. 2010 ; Vol. 9.
@article{73a5eb25a2d34bcb8429f27df2ae6e2b,
title = "NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease",
abstract = "Background: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. However, dietary cholesterol intake was superabundant in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Therefore, excess cholesterol intake appears to be one of the main factors associated with NAFLD development and liver injury. Methods. We reviewed a year of follow-up data of non-obese NAFLD patients treated with Niemann-Pick C1 like 1 inhibitor ezetimibe to evaluate its therapeutic effect on clinical parameters related to NAFLD. Without any dietary or exercise modification, 10 mg/day of ezetimibe was given to 8 patients. In 4 of 8 patients, ezetimibe was administered initially. In the remaining 4 patients, medication was switched from ursodeoxycholic acid to ezetimibe. Results: In each patient, body mass index was maintained under 25 kg/m2 during the observation period. Serum ALT levels significantly decreased within 6 months and in 4 patients levels reached the normal range (<30 U/L), which was accompanied with at least a 10{\%} decrease in serum total cholesterol and LDL-cholesterol. However, ultrasonographic findings of fatty liver did not show obvious improvement for a year. Conclusion: We conclude that the cholesterol absorption inhibitor ezetimibe can suppress hepatic injury in non-obese patients with NAFLD and that ezetimibe may offer a novel treatment for NAFLD.",
author = "Munechika Enjoji and Kazuyuki MacHida and Motoyuki Kohjima and Masaki Kato and Kazuhiro Kotoh and Kazuhisa Matsunaga and Manabu Nakashima and Makoto Nakamuta",
year = "2010",
month = "12",
day = "1",
doi = "10.1186/1476-511X-9-29",
language = "English",
volume = "9",
journal = "Lipids in Health and Disease",
issn = "1476-511X",
publisher = "BioMed Central",

}

TY - JOUR

T1 - NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

AU - Enjoji, Munechika

AU - MacHida, Kazuyuki

AU - Kohjima, Motoyuki

AU - Kato, Masaki

AU - Kotoh, Kazuhiro

AU - Matsunaga, Kazuhisa

AU - Nakashima, Manabu

AU - Nakamuta, Makoto

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Background: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. However, dietary cholesterol intake was superabundant in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Therefore, excess cholesterol intake appears to be one of the main factors associated with NAFLD development and liver injury. Methods. We reviewed a year of follow-up data of non-obese NAFLD patients treated with Niemann-Pick C1 like 1 inhibitor ezetimibe to evaluate its therapeutic effect on clinical parameters related to NAFLD. Without any dietary or exercise modification, 10 mg/day of ezetimibe was given to 8 patients. In 4 of 8 patients, ezetimibe was administered initially. In the remaining 4 patients, medication was switched from ursodeoxycholic acid to ezetimibe. Results: In each patient, body mass index was maintained under 25 kg/m2 during the observation period. Serum ALT levels significantly decreased within 6 months and in 4 patients levels reached the normal range (<30 U/L), which was accompanied with at least a 10% decrease in serum total cholesterol and LDL-cholesterol. However, ultrasonographic findings of fatty liver did not show obvious improvement for a year. Conclusion: We conclude that the cholesterol absorption inhibitor ezetimibe can suppress hepatic injury in non-obese patients with NAFLD and that ezetimibe may offer a novel treatment for NAFLD.

AB - Background: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. However, dietary cholesterol intake was superabundant in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Therefore, excess cholesterol intake appears to be one of the main factors associated with NAFLD development and liver injury. Methods. We reviewed a year of follow-up data of non-obese NAFLD patients treated with Niemann-Pick C1 like 1 inhibitor ezetimibe to evaluate its therapeutic effect on clinical parameters related to NAFLD. Without any dietary or exercise modification, 10 mg/day of ezetimibe was given to 8 patients. In 4 of 8 patients, ezetimibe was administered initially. In the remaining 4 patients, medication was switched from ursodeoxycholic acid to ezetimibe. Results: In each patient, body mass index was maintained under 25 kg/m2 during the observation period. Serum ALT levels significantly decreased within 6 months and in 4 patients levels reached the normal range (<30 U/L), which was accompanied with at least a 10% decrease in serum total cholesterol and LDL-cholesterol. However, ultrasonographic findings of fatty liver did not show obvious improvement for a year. Conclusion: We conclude that the cholesterol absorption inhibitor ezetimibe can suppress hepatic injury in non-obese patients with NAFLD and that ezetimibe may offer a novel treatment for NAFLD.

UR - http://www.scopus.com/inward/record.url?scp=77955519012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955519012&partnerID=8YFLogxK

U2 - 10.1186/1476-511X-9-29

DO - 10.1186/1476-511X-9-29

M3 - Article

C2 - 20222991

AN - SCOPUS:77955519012

VL - 9

JO - Lipids in Health and Disease

JF - Lipids in Health and Disease

SN - 1476-511X

M1 - 29

ER -